ArticleCureus2025
Comparative Efficacy of Transurethral Laser Ablation Versus Conventional Methods in the Management of Recurrent Non-Muscle-Invasive Bladder Tumours.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNon-muscle-invasive bladder cancer (NMIBC) is characterised by a high recurrence rate, necessitating frequent intervention. While conventional transurethral resection of bladder tumour (TURBT) under general anaesthesia is standard, it carries inherent risks. Transurethral laser ablation (TULA) performed under local anaesthesia in an outpatient setting presents a viable, minimally invasive alternative, yet robust comparative efficacy data remain limited. This study aimed to compare the effectiveness of TULA and TURBT in preventing early tumour recurrence and to provide practical insights for implementing an outpatient TULA service.
methodsThis retrospective cohort study included patients with recurrent NMIBC treated with either TULA or TURBT. Patient selection for the comparative analysis was restricted to those with recurrent lesions sized less than 1 cm. The TULA procedures were performed under local anaesthesia using a holmium:yttrium-aluminium-garnet (Ho:YAG) laser (Cook Medical, Ireland) and a compatible fibre. Key outcomes included the tumour recurrence rate at the first follow-up cystoscopy. Complications were assessed retrospectively over a 30-day period.
resultsA total of 97 patients were included (TULA: 51; TURBT: 46). Baseline characteristics (age, sex, and risk stratification) were comparable between the groups (p>0.05). No statistically significant difference in tumour recurrence rates was observed at the first follow-up cystoscopy: 30 patients (58.8%) in the TULA group and 27 patients (58.7%) in the TURBT group exhibited no recurrence. Furthermore, TULA demonstrated no immediate post-procedure complications requiring hospital admission. Implementation of the outpatient TULA service, prioritising staff training, safety, and a robust governance framework, proved successful in our centre.
conclusionTULA performed under local anaesthesia demonstrates possible comparable efficacy to TURBT in preventing early tumour recurrence, underscoring its potential as a reasonable alternative for managing small, recurrent NMIBC, particularly for patients at higher risk of complications from general anaesthesia. Successful establishment of an outpatient TULA service, guided by clear operational and safety protocols, enhances efficiency. Larger prospective multicentre trials with longer follow-up are warranted to fully validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.